Novel, science-backed claims enabled by biotech? Check. New hero ingredients generated by AI? Check. BiotechXBeautyLabs gives brands a shortcut to next-generation innovation.Cultura Creative
⚠️Register now; the first 100 registrants for this session and receive 10% off your first contract manufacturing order.
DebutDebut, the biotech beauty leader, recently launched a new business unit, BiotechXBeautyLabs, a biotech formulation development and contract manufacturing business that offers the ultimate competitive advantage to brands: product innovation driven by biotech.
BiotechXBeautyLabs makes it possible for all beauty brands globally to develop cutting-edge biotech formulations–minus the heavy investment associated with biotech R&D.
Through access to novel, science-backed, peak-performing formulations that are 95% bio-based, BiotechXBeautyLabs catapults brands into the biotech hemisphere, the next frontier in beauty.
➡️On Thursday, September 12, 2024 at 11:00 a.m. Central, Joshua Britton, founder and CEO of Debut, will lead Biotech: How All Brands Can Access the Next Frontier in Beauty.
During this free virtual session, Britton will discuss how biotech is pushing the boundaries of what’s next in beauty with heightened performance, true product innovation and impeccable sustainability credentials. Topics covered will include:
- How biotech delivers the ultimate competitive advantage to brands
- Novel, science-backed claims enabled by biotech
- The new hero ingredients generated by AI
- Biotech’s superior sustainability & ethical beauty standards
For the first 100 registrants, Debut is offering 10% off their first contract manufacturing order.
Who should attend:
- Brand founders & CEOs
- R&D
- Product innovation
- Marketing
⚠️Register now; the first 100 registrants for this session and receive 10% off your first contract manufacturing order.
About Joshua Britton
Joshua Britton is founder and CEO of Debut located in San Diego. Debut uses cutting-edge biotechnology to bring novel, high-performing and sustainable ingredients to the cosmetic industry.
Britton believes that the best way to deliver on the promise of biomanufacturing is to vertically integrate to product. To that end, Debut is pioneering a new business model in biology that is driving the beauty industry by discovering, testing, and commercializing high-performing ingredients, and incorporating them into valuable beauty products.
At Debut, Britton leads a rapidly growing multi-disciplinary team of over 100 people executing an aggressive commercialization strategy. Debut holds over 70 patents in ingredients and formulations. To date, Britton has raised $70 million for Debut from leading funds including BOLD, the venture capital fund of L’Oréal.
Prior to Debut, Britton was trained as a scientist at the Massachusetts Institute of Technology (MIT) where he gained a Post-Doc in Chemistry. Britton also gained a PhD in Organic Chemistry from University of California, Irvine (UCI), and a master’s degree in Organic Chemistry from Nottingham University in the UK.
Britton is an advisor to Cantos Ventures, a venture capital and private equity company that specializes in near-frontier technology.
⚠️Register now; the first 100 registrants for this session and receive 10% off your first contract manufacturing order.